Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi JP, I just saw that selling too. I agree that it is frustrating not having explanation. Weird. Especially after an investor conference.
Hi Catty,
Director Marshbanks sold some. Still owns a boatload.
Hoping Art will launch something.
Thanks for posting. Nice guidance chart!
JTFM, Thanks!
Thanks Jeff. It sounds like those pesky senior notes may keep a lid on things.
You guys stay safe in this storm!
JTFM, Thank you for explaining. Still confused. I'll work on it. lol.
Anybody else snowed in?
I do not understand the terms of the deal with the "senior notes." If that is the reason that we seem to never exceed $ 70-ish, please explain. Thank you.
JTFM, Do you think that both Antares and ANI thought Xyosted was
a done deal and they were preparing for a merger? Was that what could have prompted the buyout rumor? Thanks.
Antares has been quiet about their subsequent FDA meeting.
Nice! Thanks BB!
Thank you for the detailed explanation. Much appreciated.
209,407 shares after hours.
Hi Jeff
I don't recall exactly but there was that fake legal drama between Abbott and Teva that turned out to be both companies putting on a show to delay our sales.
I'm trying to find the transcript that describes the write down. I will post it when I find it.
Seems like a lot of money but not really after dealing with those snakes.
From the transcript:
"In addition, during the fourth quarter, we recognized a 900,000 non-cash write-off of our finite live non-core intangible asset. This intangible related to our NDA for testosterone gel, an asset that was acquired and accounted for in our 2013 merger with BioSante.
This asset was previously written down in the fourth quarter of last year. We have now officially discontinued this filing with the FDA and describe no further value on our balance sheet for this product. Our adjusted non-GAAP earnings per share metric which excludes these items was $1.08 for diluted share, an increase of $0.18 or 20% from the prior year."
I remember when Bio-T-gel was written down last year.
Good earnings report! Great company!
JTFM, Would it make sense for another company to buy our safety data? Do you know if that would be allowed by the FDA?I'm wondering about Lawley.
I thought we held up pretty well today considering the carnage. It's as if we have returned to exactly where we were pre-rumor. We will know more at our next earnings report if not sooner.
Jeff, Right. It's easy to report after the fact that you saw it in your crystal ball. JTFM has done way more DD than I have and JTFM, if you're reading this, we are beyond grateful for your generosity. We have weathered ups and downs and we are fortunate enough to have amazing cost basis. If we had a lousy CEO (as some posters imply) it would be another story. We have great, Blackrock-worthy management.
It does appear that way. 20/20 hindsight. Impressive!
dasgrunt, That's always a good sign. Thanks.
Yes. GVAX is not the example I was looking for. BPAX sold it prior to merger. Like the AstdaZeneca deal, we will continue to be surprised. Hey, what's a little more time for message board buds?
Hi JTFM,
Jeff asked me if I knew of another example of a company keeping an important, acquired asset a secret for several years, never mentioning it to shareholders. I don't know of an example but Art doesn't talk about GVAX either.
Hi Jeff, It is frustrating and it isn't right, EXCEPT, they are doing so many other things that are exceptional!I know enough to know I don't know enough!
In spite of the patent progress on libigel, my real source of inspiration are the 4 million off label scripts,the mountain of positive research data, and the data demonstrating that off label is inferior to standardized product. Are U.S. women any different than women in Australia?
Hi JTFM, Is this a common financing model? It seems logically, that with such a low float, if Q4 earnings are fabulous, we should spike. This financing model seems like a threat to increasing pps because our low float will be diluted in 16 months. I realize that the corti drugs will provide revenue to justify the dilution. I'm still confused by the hedge but I see your original point: we are manipulated, big time, by institutional investors. Thanks for sharing.
JTFM, That may be the case. I really don't understand the senior note financing. We have a very strong, growing company with incredible I.P. assets, all in a positive business climate. No where to go but up, imo.
Hi Jeff, Of the 55k, I wonder how many were playing games with their own shares trying to take it down? The Blackrock news alone spells good earnings.
Jeff, When you said that before about the new drug purchases from AsraZeneca, I didn't follow. I get it now and it makes sense. Thanks.
Blackrock acquiring this many shares is a big deal. What do you think happens next? Anybody?
Two weeks ago Mr. Przybyl gifted 850 shares to someone. I think it was a sign. Feeling very hopeful tonight fellow ANIPpers. Best of luck to all.
Two weeks ago Mr. Przybyl gifted 850 shares to someone. I think it was a sign. Feeling very hopeful tonight fellow ANIPpers. Best of luck to all.
JTFM,
Great post. Thanks.
I thought we were looking at a buyout in the short term but Art Przybyl may have positioned the company for something else. Who knows. He is very good at finding revenue and it looks like this year will be really different because of tax changes and other coming legislation that is pro-business. We got that big Lithobid contract, I think we will get more.
The corti drug deal is so expensive and as I said it makes me uncomfortable because there are so many other areas where bioidentical/biosimilar drugs are the way to go. I am NOT a medical person. It is just a sense. Synthetic corticotropin is used successfully in other countries.Maybe there are indications for only porcine based acthar gel.
I really like the new FDA director. I think we will see Libigel approved finally. All this is jmo. I appreciate your input!
Jeff, I agree that this company is 100% impressive! Another reason I think ANI might be acquiring drugs that are gov't contract money makers is that our CEO is proactive and always ahead of the curve.
US generic drug company making an asset grab in this political environment? Location location location
There is a lot of money to be made in government contracts and Atacand (for example)is a commonly used anti-hypertensive.
"American made" is a big Trump theme and it can easily be applied to pharma contracts such as VA, military,etc. AstraZeneca is a UK company. We are based in U.S. We bought the US rights to Atacand and 3 others. I believe our company is after more gov't contracts.
The following is about Government Contract Policy to Watch:
https://www.mccarter.com/files/Uploads/Documents/Website/Law360GovtContractsPolicyToWatchIn2018_Turner010118.pdf
Thanks.
IMO there will be a good market for acthar gel. Just concerned about a cheaper competitor.
The new FDA director is all about streamlining, clarity, and cost effectiveness while maintaining safety and efficacy. All good stuff IMO.
This is the transaction that makes me a little uncomfortable. There are so many cultural and religious reasons that make porcine products contraindicated:
http://www.nasdaq.com/press-release/depomed-and-sln-medicinal-holdings-ltd-announce-strategic-asset-transactions-20171107-01530
Maybe I'm missing something.
JTFM and Jeff,
Acatand has a migraine market too.
https://www.sciencedaily.com/releases/2014/01/140113104841.htm
The new FDA director is a game changer. I believe he is great for a Libigel approval but he may make us rethink our corti drug strategy.
Seems like today's buyers may have needed a couple days to process the AstraZeneca news.Hope it continues all week!
We already won a substantial federal government contract this year for vancomycin.
http://www.4-traders.com/ANI-PHARMACEUTICALS-INC-13658425/news/ANI-Pharmaceuticals-Federal-Contracts-Awarded-to-Companies-in-Minnesota-Sept-12-25104070/
Lowest bid, made in USA: We are poised to win more contracts.
I know that what we see on our screens is sometimes smoke and mirrors but seriously, who would selling today?
Jeff, So what can you read between the lines here? Are we not preparing to be acquired? Will we merge again? Will we be the acquiring company? We just took on 5 year financing.Does the 5 year term mean anything or not? AstraZeneca. Cool.
We have news ANIPers!